Correlation Between Cadrenal Therapeutics, and Unicycive Therapeutics

Can any of the company-specific risk be diversified away by investing in both Cadrenal Therapeutics, and Unicycive Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Cadrenal Therapeutics, and Unicycive Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Cadrenal Therapeutics, Common and Unicycive Therapeutics, you can compare the effects of market volatilities on Cadrenal Therapeutics, and Unicycive Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Cadrenal Therapeutics, with a short position of Unicycive Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Cadrenal Therapeutics, and Unicycive Therapeutics.

Diversification Opportunities for Cadrenal Therapeutics, and Unicycive Therapeutics

-0.53

Correlation Coefficient

Cadrenal Therapeutics,  Unicycive Therapeutics

Excellent diversification

The 3 months correlation between Cadrenal and Unicycive is -0.53. Overlapping area represents the amount of risk that can be diversified away by holding Cadrenal Therapeutics, Common and Unicycive Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Unicycive Therapeutics and Cadrenal Therapeutics, is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Cadrenal Therapeutics, Common are associated (or correlated) with Unicycive Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Unicycive Therapeutics has no effect on the direction of Cadrenal Therapeutics, i.e., Cadrenal Therapeutics, and Unicycive Therapeutics go up and down completely randomly.

Pair Corralation between Cadrenal Therapeutics, and Unicycive Therapeutics

Given the investment horizon of 90 days Cadrenal Therapeutics, Common is expected to generate 0.99 times more return on investment than Unicycive Therapeutics. However, Cadrenal Therapeutics, Common is 1.01 times less risky than Unicycive Therapeutics. It trades about 0.12 of its potential returns per unit of risk. Unicycive Therapeutics is currently generating about -0.08 per unit of risk. If you would invest  1,423  in Cadrenal Therapeutics, Common on December 30, 2024 and sell it today you would earn a total of  423.00  from holding Cadrenal Therapeutics, Common or generate 29.73% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Very Weak
Accuracy	100.0%
Values	Daily Returns

Cadrenal Therapeutics, Common  vs.  Unicycive Therapeutics

Cadrenal Therapeutics,

Risk-Adjusted Performance

OK

Compared to the overall equity markets, risk-adjusted returns on investments in Cadrenal Therapeutics, Common are ranked lower than 9 (%) of all global equities and portfolios over the last 90 days. In spite of rather uncertain forward-looking signals, Cadrenal Therapeutics, exhibited solid returns over the last few months and may actually be approaching a breakup point.

Unicycive Therapeutics

Risk-Adjusted Performance

Very Weak

Over the last 90 days Unicycive Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's fundamental indicators remain fairly strong which may send shares a bit higher in April 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Pair Trading with Cadrenal Therapeutics, and Unicycive Therapeutics

The main advantage of trading using opposite Cadrenal Therapeutics, and Unicycive Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Cadrenal Therapeutics, position performs unexpectedly, Unicycive Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Unicycive Therapeutics will offset losses from the drop in Unicycive Therapeutics' long position.

The idea behind Cadrenal Therapeutics, Common and Unicycive Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.